Co-Authors
This is a "connection" page, showing publications co-authored by Zachary Wallace and Jeffrey Sparks.
Connection Strength
3.348
-
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. Curr Opin Rheumatol. 2021 09 01; 33(5):412-418.
Score: 0.241
-
Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 23.
Score: 0.241
-
Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 13.
Score: 0.240
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.237
-
Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatol. 2021 Sep; 3(9):e638-e647.
Score: 0.237
-
Incident systemic rheumatic disease following COVID-19. Lancet Rheumatol. 2021 Jun; 3(6):e402-e404.
Score: 0.235
-
Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by Shanoj et al. Ann Rheum Dis. 2021 Mar 10.
Score: 0.233
-
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. Ann Rheum Dis. 2021 Jan 12.
Score: 0.231
-
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis. 2021 05; 80(5):660-666.
Score: 0.229
-
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al. Ann Rheum Dis. 2020 Jul 13.
Score: 0.223
-
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al. Ann Rheum Dis. 2020 Jun 25.
Score: 0.222
-
Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao et al. Ann Rheum Dis. 2021 05; 80(5):e64.
Score: 0.222
-
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis. 2020 09; 79(9):1156-1162.
Score: 0.221
-
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021 Oct; 3(10):e707-e714.
Score: 0.060
-
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 03; 73(3):374-380.
Score: 0.058
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
Score: 0.058
-
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis Rheumatol. 2021 01; 73(1):36-47.
Score: 0.057
-
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum. 2020 10; 50(5):1191-1201.
Score: 0.056
-
Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. Arthritis Care Res (Hoboken). 2018 03; 70(3):445-453.
Score: 0.047